A single hERG mutation underlying a spectrum of acquired and congenital long QT syndrome phenotypes

Journal of Molecular and Cellular Cardiology

Volumn 43, Issue 1, 2007, Pages 63-72

  Saenen, J B ^a   Paulussen, A D C ^b,c   Jongbloed, R J ^b,c   Marcelis, C L ^b   Gilissen, R A H J ^d   Aerssens, J ^d   Snyders, D J ^a   Raes, A L ^a  

^a Laboratory for Molecular Biophysics   (Belgium)

^b MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^c MAASTRICHT UNIVERSITY   (Netherlands)

^d JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

Author keywords

Acquired; Arrhythmia; Congenital; Correlation; Genotype; hERG; Ion channel; Long QT syndrome; Phenotype; Polymorphism; Potassium; Spectrum; Sudden cardiac death

Indexed keywords

POTASSIUM CHANNEL; POTASSIUM CHANNEL HERG; PROLINE; SERINE;

ADULT; ARTICLE; BIOPHYSICS; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DENMARK; EMBRYO; FAMILY; FEMALE; GENE EXPRESSION; GENE MUTATION; GENETIC HETEROGENEITY; GENETIC PREDISPOSITION; GENOTYPE; GENOTYPE PHENOTYPE CORRELATION; HUMAN; HUMAN CELL; LONG QT SYNDROME; MALE; NETHERLANDS; PATCH CLAMP; PHENOTYPE; PRIORITY JOURNAL; SPECTRUM; WHOLE CELL;

AGED; AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; BASE SEQUENCE; CANADA; CELL LINE; ETHER-A-GO-GO POTASSIUM CHANNELS; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GENETIC DISEASES, INBORN; HUMANS; LONG QT SYNDROME; NETHERLANDS; PEDIGREE; PHENOTYPE; POINT MUTATION;

EID: 34250207712     PISSN: 00222828     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.yjmcc.2007.04.012     Document Type: Article

References (42)

1. Priori S.G., Barhanin J., Hauer R.N., Haverkamp W., Jongsma H.J., Kleber A.G., et al. Genetic and molecular basis of cardiac arrhythmias: impact on clinical management: Parts I and II. Circulation 99 4 (1999) 518-528
2. Priori S.G., Barhanin J., Hauer R.N., Haverkamp W., Jongsma H.J., Kleber A.G., et al. Genetic and molecular basis of cardiac arrhythmias: impact on clinical management: Part III. Circulation 99 5 (1999) 674-681
3. Chiang C.E., and Roden D.M. The long QT syndromes: genetic basis and clinical implications. J. Am. Coll. Cardiol. 36 1 (2000) 1-12
4. Mitcheson J.S., Chen J., Lin M., Culberson C., and Sanguinetti M.C. A structural basis for drug-induced long QT syndrome. Proc. Natl. Acad. Sci. U. S. A. 97 22 (2000) 12329-12333
5. Ackerman M.J. Molecular basis of congenital and acquired long QT syndromes. J. Electrocardiol. 37 (2004) 1-6 (Suppl.)
6. Kr potassium channels with HERG and is associated with cardiac arrhythmia. Cell 97 2 (1999) 175-187
7. + channel splice variant common in human heart lacks a C-terminal domain required for expression of rapidly-activating delayed rectifier current. J. Biol. Chem. 273 (1998) 27231-27235
8. Mohler P.J., Schott J.J., Gramolini A.O., Dilly K.W., Guatimosim S., duBell W.H., et al. Ankyrin-B mutation causes type 4 long-QT cardiac arrhythmia and sudden cardiac death. Nature 421 6923 (2003) 634-639
9. Roden D.M. Drug-induced prolongation of the QT interval. N. Engl. J. Med. 350 10 (2004) 1013-1022
10. Schwartz P.J., Priori S.G., Spazzolini C., Moss A.J., Vincent G.M., Napolitano C., et al. Genotype-phenotype correlation in the long-QT syndrome: gene-specific triggers for life-threatening arrhythmias. Circulation 103 1 (2001) 89-95
11. Priori S.G., Napolitano C., and Schwartz P.J. Low penetrance in the long-QT syndrome: clinical impact. Circulation 99 4 (1999) 529-533
12. Yang P., Kanki H., Drolet B., Yang T., Wei J., Viswanathan P.C., et al. Allelic variants in long-QT disease genes in patients with drug-associated torsades de pointes. Circulation 105 16 (2002) 1943-1948
13. Kaab S., and Schulze-Bahr E. Susceptibility genes and modifiers for cardiac arrhythmias. Cardiovasc. Res. 67 3 (2005) 397-413
14. Crotti L., Lundquist A.L., Insolia R., Pedrazzini M., Ferrandi C., De Ferrari G.M., et al. KCNH2-K897T is a genetic modifier of latent congenital long-QT syndrome. Circulation 112 9 (2005) 1251-1258
15. Kr channels minimally comprise hERG 1a and 1b subunits. J. Biol. Chem. 279 43 (2004) 44690-44694
16. Kr channel. J. Gen. Physiol. 107 (1996) 611-619
17. Zhou Z., Gong Q., Ye B., Fan Z., Makielski J.C., Robertson G.A., et al. Properties of HERG channels stably expressed in HEK 293 cells studied at physiological temperature. Biophys. J. 74 1 (1998) 230-241
18. Akar F.G., Yan G.X., Antzelevitch C., and Rosenbaum D.S. Unique topographical distribution of M cells underlies reentrant mechanism of torsade de pointes in the long-QT syndrome. Circulation 105 10 (2002) 1247-1253
19. Fernandez D., Ghanta A., Kauffman G.W., and Sanguinetti M.C. Physicochemical features of the HERG channel drug binding site. J. Biol. Chem. 279 11 (2004) 10120-10127
20. Sanguinetti M.C., and Tristani-Firouzi M. hERG potassium channels and cardiac arrhythmia. Nature 440 7083 (2006) 463-469
21. Piquette R.K. Torsade de pointes induced by cisapride/clarithromycin interaction. Ann. Pharmacother. 33 1 (1999) 22-26
22. Jongbloed R., Marcelis C., Velter C., Doevendans P., Geraedts J., and Smeets H. DHPLC analysis of potassium ion channel genes in congenital long QT syndrome. Hum. Mutat. 20 5 (2002) 382-391
23. Wang Q., Li Z., Shen J., and Keating M.T. Genomic organization of the human SCN5A gene encoding the cardiac sodium channel. Genomics 34 1 (1996) 9-16
24. Schwartz P.J., Moss A.J., Vincent G.M., and Crampton R.S. Diagnostic criteria for the long QT syndrome. An update. Circulation 88 2 (1993) 782-784
25. Viloria C.G., Barros F., Giraldez T., Gomez-Varela D., and de la P.P. Differential effects of amino-terminal distal and proximal domains in the regulation of human erg K(+) channel gating. Biophys. J. 79 1 (2000) 231-246
26. Paulussen A.D., Raes A., Jongbloed R.J., Gilissen R.A., Wilde A.A., Snyders D.J., et al. HERG mutation predicts short QT based on channel kinetics but causes long QT by heterotetrameric trafficking deficiency. Cardiovasc. Res. 67 3 (2005) 467-475
27. Sesti F., Abbott G.W., Wei J., Murray K.T., Saksena S., Schwartz P.J., et al. A common polymorphism associated with antibiotic-induced cardiac arrhythmia. Proc. Natl. Acad. Sci. U. S. A. 97 19 (2000) 10613-10618
28. Potet F., Bouyssou T., Escande D., and Baro I. Gastrointestinal prokinetic drugs have different affinity for the human cardiac human ether-a-gogo K(+) channel. J. Pharmacol. Exp. Ther. 299 3 (2001) 1007-1012
29. Volberg W.A., Koci B.J., Su W., Lin J., and Zhou J. Blockade of human cardiac potassium channel human ether-a-go-go-related gene (HERG) by macrolide antibiotics. J. Pharmacol. Exp. Ther. 302 1 (2002) 320-327
30. Paulussen A.D., Gilissen R.A., Armstrong M., Doevendans P.A., Verhasselt P., Smeets H.J., et al. Genetic variations of KCNQ1, KCNH2, SCN5A, KCNE1, and KCNE2 in drug-induced long QT syndrome patients. J. Mol. Med. 82 3 (2004) 182-188
31. Khan I.A. Long QT syndrome: diagnosis and management. Am. Heart J. 143 1 (2002) 7-14
32. Saenen J.B., Labro A.J., Raes A.L., and Snyders D.J. Modulation of hERG gating by a charge cluster in the N-terminal 'proximal' domain. Biophys. J. 91 (2006) 4381-4391
33. Wang S., Liu S., Morales M.J., Strauss H.C., and Rasmusson R.L. A quantitative analysis of the activation and inactivation kinetics of HERG expressed in Xenopus oocytes. J. Physiol. (London) 502 Pt 1 (1997) 45-60
34. Thomas D., Kiehn J., Katus H.A., and Karle C.A. Defective protein trafficking in hERG-associated hereditary long QT syndrome (LQT2): molecular mechanisms and restoration of intracellular protein processing. Cardiovasc. Res. 60 2 (2003) 235-241
35. Anderson C.L., Delisle B.P., Anson B.D., Kilby J.A., Will M.L., Tester D.J., et al. Most LQT2 mutations reduce Kv11.1 (hERG) current by a class 2 (trafficking-deficient) mechanism. Circulation 113 3 (2006) 365-373
36. Iyer V., Mazhari R., and Winslow R.L. A computational model of the human left-ventricular epicardial myocyte. Biophys. J. 87 3 (2004) 1507-1525
37. Splawski I., Shen J., Timothy K.W., Lehmann M.H., Priori S., Robinson J.L., et al. Spectrum of mutations in long-QT syndrome genes. KVLQT1, HERG, SCN5A, KCNE1, and KCNE2. Circulation 102 10 (2000) 1178-1185
38. Ackerman M.J., Tester D.J., Jones G.S., Will M.L., Burrow C.R., and Curran M.E. Ethnic differences in cardiac potassium channel variants: implications for genetic susceptibility to sudden cardiac death and genetic testing for congenital long QT syndrome. Mayo Clin. Proc. 78 12 (2003) 1479-1487
39. Roden D.M. Long QT syndrome: reduced repolarization reserve and the genetic link. J. Intern. Med. 259 1 (2006) 59-69
40. Varro A., and Papp J.G. Low penetrance, subclinical congenital LQTS: concealed LQTS or silent LQTS?. Cardiovasc. Res. 70 3 (2006.) 404-406
41. Lee M.P., Hu R.J., Johnson L.A., and Feinberg A.P. Human KVLQT1 gene shows tissue-specific imprinting and encompasses Beckwith-Wiedemann syndrome chromosomal rearrangements. Nat. Genet. 15 2 (1997) 181-185
42. Donger C., Denjoy I., Berthet M., Neyroud N., Cruaud C., Bennaceur M., et al. KVLQT1 C-terminal missense mutation causes a forme fruste long-QT syndrome. Circulation 96 9 (1997) 2778-2781